Abstract Body

Background: In recent years there have been multiple epidemics of Hepatitis C (HCV) co-infection in HIV-infected populations. The early identification of acute HCV infection can have important implications for both treatment and partner notification to reduce onwards transmission. Acute HCV infection is diagnosed using HCV RNA testing methods which are more sensitive and specific then HCV antibody tests, particularly in immunosuppressed patients. Recently tests against the core antigen of HCV have become available. Our aim was to compare HCV core antigen and HCV RNA testing in the detection of early HCV infection. Methodology: 100 HIV-infected individuals who presented with isolated alanine transaminase (ALT) values above the upper limit of normal at routine blood sampling (>41 IU) were tested for acute HCV infection using HCV core antigen testing (Abbott Archetect +/- Biorad), HCV RNA viral load (Abbott Real Time PCR (qRT-PCR) and standard in house HCV antibody testing. A cut off value for quantitative HCV antigen testing of 5.0 IU/mL was used in the analysis. Sequential samples were collected over a twelve month period between April 2012 and October 2013. Retrospective testing of previously stored serum samples determined which infections were acute; chronic HCV infections were excluded from the analysis. All HCV positive patients were genotyped and entered into a co-infection clinic for assessment and treatment in accordance with local guidelines. Results: The mean age of patients was 41 years (27-73), 6 were female, 77% were MSM, 6% were of Black ethnicity and 4% reported IVDU. None had pre-existing liver disease and no alternative cause of raised ALT had been previously identified. Genotype 1aor 1b predominated (90%). Fifteen cases of acute HCV were identified during the 18 months of this study screening isolated ALT rises alone. All 15 were identified by the HCV RNA PCR. HCV antigen testing initially identified 13 positive and 2 ‘indeterminate’ results; these became positive on retesting. On serology, five patients were HCV antibody negative and 4 showed only a weak positive signal at the time sampled. Conclusions: With the increase in HCV infections amongst HIV-infected populations, a quick, easy and cost-effective method of testing for acute HCV is needed. HCV antigen testing may offer an alternative to HCV PCR as a screening tool in the clinical setting. Relying on HCV antibody tests as a screening tool is likely to miss some acute infections.